Company intelligence / Profile preview

Securitas Biosciences

São Paulo, São Paulo, Brazilsecuritasbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Securitas Biosciences operates as a venture builder specializing in advanced therapies for rare diseases and niche indications. It leverages synthetic biology, AI-driven drug discovery tools, gene therapy platforms, vaccine development technologies, and partnerships with leading Latin American research institutions. The company advances programs internally through preclinical/early clinical stages before outlicensing or spinning them out for further development. No published late-stage clinical results were identified.

Modalities: Gene therapyOncolytic virus therapyVaccine
Industry: Biotech

Partnerships

Hospital Italiano [Argentina]Instituto Leloir [Argentina]

Beyond the preview

Go deeper on Securitas Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Securitas Biosciences.

Explore the full profile